These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38113294)

  • 21. Non-alcoholic fatty liver is associated with increased risk of irritable bowel syndrome: a prospective cohort study.
    Wu S; Yuan C; Yang Z; Liu S; Zhang Q; Zhang S; Zhu S
    BMC Med; 2022 Aug; 20(1):262. PubMed ID: 35989356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease.
    Munteanu M; Pais R; Peta V; Deckmyn O; Moussalli J; Ngo Y; Rudler M; Lebray P; Charlotte F; Thibault V; Lucidarme O; Ngo A; Imbert-Bismut F; Housset C; Thabut D; Ratziu V; Poynard T;
    Aliment Pharmacol Ther; 2018 Nov; 48(10):1117-1127. PubMed ID: 30334263
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interval increase in the prevalence of symptomatic cholelithiasis-associated non-alcoholic fatty liver disease over a ten-year period in an Asian population.
    Khaw KB; Choi RH; Kam JH; Chakraborty B; Chow PK
    Singapore Med J; 2017 Dec; 58(12):703-707. PubMed ID: 27995261
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of non-alcoholic fatty liver disease on incident type 2 diabetes mellitus in non-overweight individuals.
    Fukuda T; Hamaguchi M; Kojima T; Hashimoto Y; Ohbora A; Kato T; Nakamura N; Fukui M
    Liver Int; 2016 Feb; 36(2):275-83. PubMed ID: 26176710
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Diagnostic significance of clinical and laboratory indices in predicting non-alcoholic fatty liver disease during screening studies].
    Nosov AE; Zenina MT; Gorbushina OY; Baidina AS; Vlasova EM; Alekseev VB
    Ter Arkh; 2021 Aug; 93(8):883-889. PubMed ID: 36286882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies.
    Jarvis H; Craig D; Barker R; Spiers G; Stow D; Anstee QM; Hanratty B
    PLoS Med; 2020 Apr; 17(4):e1003100. PubMed ID: 32353039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-Alcoholic Fatty Liver Disease (NAFLD) and risk of new-onset heart failure: a retrospective analysis of 173,966 patients.
    Roderburg C; Krieg S; Krieg A; Vaghiri S; Mohr R; Konrad M; Luedde M; Luedde T; Kostev K; Loosen SH
    Clin Res Cardiol; 2023 Oct; 112(10):1446-1453. PubMed ID: 37410163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-alcoholic Fatty Liver Disease Is Associated With Aortic Calcification: A Cohort Study With Propensity Score Matching.
    Zhu RR; Gao XP; Liao MQ; Cui YF; Tan SX; Zeng FF; Lou YM; Wang CY; Xu S; Peng XL; Dai SH; Zhao D; Wang L; Ping Z; Dai XY; Feng PN; Han LY
    Front Endocrinol (Lausanne); 2022; 13():880683. PubMed ID: 35651978
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven non-alcoholic fatty liver disease.
    Nobili V; Mantovani A; Cianfarani S; Alisi A; Mosca A; Sartorelli MR; Maffeis C; Loomba R; Byrne CD; Targher G
    J Hepatol; 2019 Oct; 71(4):802-810. PubMed ID: 31279904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The albumin-to-alkaline phosphatase ratio as an independent predictor of future non-alcoholic fatty liver disease in a 5-year longitudinal cohort study of a non-obese Chinese population.
    Sheng G; Peng N; Hu C; Zhong L; Zhong M; Zou Y
    Lipids Health Dis; 2021 May; 20(1):50. PubMed ID: 33993872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic syndrome and biochemical changes among non-alcoholic fatty liver disease patients attending a tertiary care hospital of Nepal.
    Pardhe BD; Shakya S; Bhetwal A; Mathias J; Khanal PR; Pandit R; Shakya J; Joshi HO; Marahatta SB
    BMC Gastroenterol; 2018 Jul; 18(1):109. PubMed ID: 29980170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease.
    Bessissow T; Le NH; Rollet K; Afif W; Bitton A; Sebastiani G
    Inflamm Bowel Dis; 2016 Aug; 22(8):1937-44. PubMed ID: 27379445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Repeatedly Elevated Fatty Liver Index Is Associated With Increased Mortality: A Population-Based Cohort Study.
    Lee CH; Han KD; Kim DH; Kwak MS
    Front Endocrinol (Lausanne); 2021; 12():638615. PubMed ID: 33776934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Epidemiology of non-alcoholic steatohepatitis. Extent/burden of the problem and its impact on public health].
    Vallet-Pichard A; Parlati L; Pol S
    Presse Med; 2019 Dec; 48(12):1459-1467. PubMed ID: 31757728
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis.
    Patel PJ; Banh X; Horsfall LU; Hayward KL; Hossain F; Johnson T; Stuart KA; Brown NN; Saad N; Clouston A; Irvine KM; Russell AW; Valery PC; Williams S; Powell EE
    Intern Med J; 2018 Feb; 48(2):144-151. PubMed ID: 29083080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low Awareness of Nonalcoholic Fatty Liver Disease in a Population-Based Cohort Sample: the CARDIA Study.
    Cleveland ER; Ning H; Vos MB; Lewis CE; Rinella ME; Carr JJ; Lloyd-Jones DM; VanWagner LB
    J Gen Intern Med; 2019 Dec; 34(12):2772-2778. PubMed ID: 31595464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD.
    Corey KE; Pitts R; Lai M; Loureiro J; Masia R; Osganian SA; Gustafson JL; Hutter MM; Gee DW; Meireles OR; Witkowski ER; Richards SM; Jacob J; Finkel N; Ngo D; Wang TJ; Gerszten RE; Ukomadu C; Jennings LL
    J Hepatol; 2022 Jan; 76(1):25-33. PubMed ID: 34600973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Application of heme oxygenase 1 in the diagnosis of non-alcoholic fatty liver disease].
    Yuan XW; Li DD; Liu LD; Zhang Y; Zhao W; Cui LY; Yang Y; Nan YM
    Zhonghua Gan Zang Bing Za Zhi; 2019 Apr; 27(4):291-297. PubMed ID: 31082341
    [No Abstract]   [Full Text] [Related]  

  • 39. Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease.
    Bertot LC; Adams LA
    Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):179-187. PubMed ID: 30791782
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An extended fatty liver index to predict non-alcoholic fatty liver disease.
    Kantartzis K; Rettig I; Staiger H; Machann J; Schick F; Scheja L; Gastaldelli A; Bugianesi E; Peter A; Schulze MB; Fritsche A; Häring HU; Stefan N
    Diabetes Metab; 2017 Jun; 43(3):229-239. PubMed ID: 28089502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.